Full Prescribing
Information
About Naropin > Benefits vs Bupivacaine > Opioid Reduction
Opioid Reduction
Choose NAROPIN® for a Significant Reduction in the Need of Opioids1-4
Chart 1: NAROPIN Showed a Higher Quality of Anesthesia vs Bupivacaine as Measured by the Intraoperative Need for Opioids1
Only 10% of NAROPIN patients required opioids vs 23.3% of bupivacaine patients at equal concentrations of 0.5%.1
Significantly Reduced Need for Opiods for Postoperative Pain3,4
At concentrations of 0.2%, NAROPIN patients who underwent lumbar plexus block experienced a 60% reduction in opioid requirement for postoperative pain vs patient-controlled morphine alone (P=0.023)3
- A reduction in opioid use results in reduced nausea and vomiting
Clinical studies demonstrated adequate analgesia and significant reduction in the need for opioids with NAROPIN 0.2% administered for nonprogressive motor block4
NAROPIN is indicated for the production of local or regional anesthesia for surgery and for acute pain management.
1. Bertini L, Tageriello V, Mancini S, et al. 0.75% and 0.5% ropivacaine for axillary brachial plexus block: a clinical comparison with 0.5% bupivacaine. Reg Anesth Pain Med. 1999;24:514-518.
2. NAROPIN Prescribing Information. Data on file.
3. Chelly JE, Casati A, Al-Samsam T, Coupe K, Criswell A, Tucker J. Continuous lumbar plexus block for acute postoperative pain management after open reduction and internal fixation of acetabular fractures. J Orthop Trauma. 2003;17:362-367.
4. Turner G, Blake M, Buckland D, et al. Continuous extradural infusion of ropivacaine for prevention of postoperative pain after major orthopaedic surgery. Br J Anaesth. 1996;76:606-610.
Important Safety Information
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
New Safety Information
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
Please see Full Prescribing Information at www.naropin-us.com.
®
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
New Safety Information
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
Please see Full Prescribing Information at www.naropin-us.com.
NAROPIN® and logo are registered trademarks of APP Pharmaceuticals, LLC.
®and APP® are registered trademarks of APP Pharmaceuticals, LLC.
©2010, APP Pharmaceuticals, LLC. All Rights Reserved.